Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug 6:3:81.
doi: 10.1186/1752-0509-3-81.

Optimal drug combinations and minimal hitting sets

Affiliations

Optimal drug combinations and minimal hitting sets

Alexei Vazquez. BMC Syst Biol. .

Abstract

Background: Identifying effective drug combinations that significantly improve over single agents is a challenging problem. Pairwise combinations already represent a huge screening effort. Beyond two drug combinations the task seems unfeasible.

Results: In this work we introduce a method to uncover drug combinations with a putative effective response when presented to a heterogeneous population of malignant agents (strains), such as cancer cell lines or viruses. Using data quantifying the effect of single drugs over several individual strains, we search for minimal drug combinations that successfully target all strains. We show that the latter problem can be mapped to a minimal hitting set problem in mathematics. We illustrate this approach using data for the NCI60 panel of tumor derived cell lines, uncovering 14 anticancer drug combinations.

Conclusion: The drug-response graph and the associated minimal hitting set method can be used to uncover effective drug combinations in anticancer drug screens and drug development programs targeting heterogeneous populations of infectious agents such as HIV.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Strain-drug response graph and the hitting set problem. A strain-drug response graph with squares representing strains, circles representing drugs, and edges representing a good response of the strain at one end to the drug at the other end. Covered circles represent drugs that are in our cocktail and empty those that are not.
Figure 2
Figure 2
NCI60 case study. a) Distribution of the normalized IC50 for three different chemical agents (bars) and the same distribution for all (cell line, drug) pairs (solid line). Δlog10IC50 denotes the log10IC50 change relative to the drug dependent mean over all cell lines. s denotes the standard deviation of Δlog10IC50 over all (cell line, drug) pairs. The dashed line marks the threshold at two standard deviations above the mean. b) The fraction pk of drugs connected to k strains in the NCI60 strain-drug response graph (symbols). The solid line represents the best fit to an exponential decay. c) Graphical representation of the minimal hitting set number 1 in Table 1.
Figure 3
Figure 3
Minimal hitting sets for incomplete drug-response graphs. When information about the response of some strains to some drugs is unavailable the strain-drug response graph is incomplete. This could result in an overestimate of the size of the minimal hitting set. a) For example, if the response of strain 3 to drug 1 has not been tested, and the corresponding edge is missing (dashed line), we will be force to cover drug 2. This will increase the minimal hitting set size from 2 to 3 drugs. b) Estimated minimal hitting set size of the NCI60 strain-drug response graph, after assuming that only a certain fraction of the interactions were tested. Note that data for 10% of the strain-drug pairs was already missing from the original dataset and, therefore, we cannot go beyond 90%. The dashed-dotted, solid and dashed line represent the minimum, average and maximum minimal hitting set sizes over 100 incomplete strain-drug response graphs. For each graph the minimal hitting set was estimated using 100 runs of the highest-degree-first algorithm.

Similar articles

Cited by

References

    1. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehár J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, Keith CT. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA. 2003;100:7977–7982. doi: 10.1073/pnas.1337088100. - DOI - PMC - PubMed
    1. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nature Rev Cancer. 2006;6:813–823. doi: 10.1038/nrc1951. - DOI - PubMed
    1. wong PK, Yu F, Shahangian A, Cheng G, Sun R, Ho C. Closed-loop control of cellular functions using combinatory grugs guided by a stochastic search algorithm. Proc Natl Acad Sci USA. 2008;105:5105–5110. doi: 10.1073/pnas.0800823105. - DOI - PMC - PubMed
    1. Yildirim MA, Goh KL, Cusick M, Barabási AL, Vidal M. Drug-target network. Nature Biotech. 2007;25:1119–1126. doi: 10.1038/nbt1338. - DOI - PubMed
    1. Nelander S, Wang W, Nilsson B, She QB, Pratilas C, Rosen N, Gennemark P, Sander C. Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol. 2008;4:216. doi: 10.1038/msb.2008.53. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources